Ben Ewald1, Brita Pekarsky. 1. Central Australian Division of General Practice, Alice Springs, NT. bewald@cceb.newcastle.edu.au
Abstract
OBJECTIVE: To compare the cost of ambulatory blood pressure monitoring (ABPM) with the putative savings made through treatment avoided by identification and non-treatment of those with "white coat" hypertension. DESIGN: A cost analysis based on a model of four alternative strategies (no ABPM, yearly, two-yearly, or three-yearly monitoring) over a seven-year period applied to a case series from Australian general practice. PARTICIPANTS: 62 patients newly diagnosed by their GPs as having hypertension and requiring drug treatment. MAIN OUTCOME MEASURES: The proportion of patients shown to not need treatment. The discounted costs to the Pharmaceutical Benefits Scheme, Medical Benefits Scheme and patients. RESULTS: 16 of 62 patients (26%; 95% CI, 15%-37%) were normotensive on ABPM and did not require treatment. All monitoring strategies are more expensive in the first year, but the initial costs are offset by year 3 and the monitoring strategies are cost saving thereafter. Sensitivity analysis shows that this result holds across a range of costs of pharmacotherapy and proportion of patients with white coat hypertension. CONCLUSION: The additional costs of 24-hour ABPM in the first year are offset by savings associated with patients with white coat hypertension who would otherwise have been treated.
OBJECTIVE: To compare the cost of ambulatory blood pressure monitoring (ABPM) with the putative savings made through treatment avoided by identification and non-treatment of those with "white coat" hypertension. DESIGN: A cost analysis based on a model of four alternative strategies (no ABPM, yearly, two-yearly, or three-yearly monitoring) over a seven-year period applied to a case series from Australian general practice. PARTICIPANTS: 62 patients newly diagnosed by their GPs as having hypertension and requiring drug treatment. MAIN OUTCOME MEASURES: The proportion of patients shown to not need treatment. The discounted costs to the Pharmaceutical Benefits Scheme, Medical Benefits Scheme and patients. RESULTS: 16 of 62 patients (26%; 95% CI, 15%-37%) were normotensive on ABPM and did not require treatment. All monitoring strategies are more expensive in the first year, but the initial costs are offset by year 3 and the monitoring strategies are cost saving thereafter. Sensitivity analysis shows that this result holds across a range of costs of pharmacotherapy and proportion of patients with white coat hypertension. CONCLUSION: The additional costs of 24-hour ABPM in the first year are offset by savings associated with patients with white coat hypertension who would otherwise have been treated.
Authors: Shia T Kent; Daichi Shimbo; Lei Huang; Keith M Diaz; Anthony J Viera; Meredith Kilgore; Suzanne Oparil; Paul Muntner Journal: J Am Soc Hypertens Date: 2014-10-02
Authors: Y Claire Wang; Alisa M Koval; Miyabi Nakamura; Jonathan D Newman; Joseph E Schwartz; Patricia W Stone Journal: Blood Press Monit Date: 2013-02 Impact factor: 1.444
Authors: Luis J Mena; Vanessa G Felix; Rodolfo Ostos; Jesus A Gonzalez; Armando Cervantes; Armando Ochoa; Carlos Ruiz; Roberto Ramos; Gladys E Maestre Journal: Comput Math Methods Med Date: 2013-05-09 Impact factor: 2.238